期刊文献+

玻璃体腔注射ranibizumab对增殖性糖尿病视网膜病变微创玻璃体视网膜手术影响 被引量:10

The effect of intravitreal ranibizumab to microincision vitreoretinal surgery for proliferative diabetic retinopathy
原文传递
导出
摘要 目的观察手术前玻璃体腔注射抗血管内皮生长因子(VEGF)单克隆抗体ranibizumab(IVR)对严重增殖性糖尿病视网膜病变(PDR)微创玻璃体视网膜手术(VRS)的影响。方法采用回顾性非随机临床对照研究。对2012年8月至2013年12月在天津市眼科医院临床确诊为严重PDR的81例100只眼纳人研究。依据术前是否行IVR将患者分为IVR组和对照组。IVR组41例50只眼,对照组40例50只眼。IVR组于手术前3~4d行玻璃体腔注射10mg/ml的ranibizumab0.05ml(含ranibizumab0.5mg),然后行23G微创VRS。对照组直接行23G微创VRS。对比分析:两组平均手术时间、新生血管出血平均次数、电凝使用平均次数、平均器械交换次数、医源性视网膜裂孔发生率、视网膜切开率。结果IVR组患者注药后均未发生与药物相关的局部及全身不良反应。IVR组、对照组平均手术时间分别为(87.43±29.34)、(100.86±17.21)min,差异具有统计学意义(t=-2.34,P〈0.05)。IVR组、对照组术中新生血管出血平均次数分别为(0.66±0.72)、(1.44±1.23)次,差异具有统计学意义(t=-4.13,P〈0.05);IVR组、对照组术中电凝使用平均次数分别为(0.30±0.58)、(0.82±0.94)次,差异具有统计学意义(t=-3.33,P〈0.05)。IVR组、对照组术中平均器械交换次数分别为(15.28±5.35)、(23.47±7.32)次,差异具有统计学意义(t=4.56,P〈0.05)。IVR组、对照组术中医源性视网膜裂孔发生率分别为2%、16%,差异具有统计学意义(r=5.98,P〈0.05)。IVR组、对照组术中视网膜切开率分别为14%、32%,差异具有统计学意义(r=4.57,P〈0.05)。结论手术前IVR能够有效地易化PDR患者VRS,并且降低手术中并发症的发生率。 Objective To observe the effect of intravitreal anti-vascular endothelial growth factor (VEGF) monoclonal antibody ranibizumab (IVR) as a preoperative adjunct in microincision vitreoreti- nal surgery (VRS) for severe proliferative diabetic retinopathy (PDR). Methods A prospective non-randomized controlled clinical study. A total of 81 patients (100 eyes) with severe PDR diag- nosed were enrolled and divided into IVR group (41 patients, 50 eyes) and control group (40 pa- tients, 50 eyes). IVR group patients received an intravitreal injection of 0.05ml ranibizumab solution (10mg/ml) first, and 3 or 4 days later they received 23G microincision VRS. Control group patients only received 23G microincision VRS. The surgical mean time, the mean number of hemorrhage in retinal neovascularization, the mean number of endodiathermy, the mean tool exchanges, the inci- dence of iatrogenic retinal breaks, and the incidence of relax retinotomy were comparatively ana-lyzed. Results There was no topical and systemic adverse reactions associated with the drug after injection in IVR group. The surgical mean time of IVR group [(87.43±29.34) min] was shorter than that of control group [(100.86±17.21) min], the difference was statistically significant (t =-2.34, P 〈 0.05). The mean number of hemorrhage in retinal neovascularization of IVR group (0.66±0.72) was shorter than that of control group (1.44±1.23), the difference was statistically significant (t =-4.13, P 〈0.05). The mean number of endodiathermy of IVR group (0.30±0.58) was shorter than that of control group (0.82+0.94), the difference was statistically significant (t =-3.33, P 〈0.05). The mean tool exchanges of IVR group (15.28±5.35)was shorter than that of control group (23.47±7.32), the difference was statistically significant (t =4.56, P 〈0.05). The incidence of iatrogenic retinal breaks in IVR group (2%) was lower than that in control group (16%), the difference was statistically sig- nificant (t =4.40, P 〈0.05). The incidence of relax retinotomy in IVR group (14%) was lower than that in control group (32%), the difference was statistically significant (t =4.57, P 〈0.05). Conclusions IVR as a preoperative adjunct in vitrectomy can make the surgery easier for PDR which achieves lower incidence of intraoperative complications.
出处 《中国实用眼科杂志》 2015年第5期467-470,共4页 Chinese Journal of Practical Ophthalmology
关键词 增殖性糖尿病视网膜病变 RANIBIZUMAB 玻璃体腔注射 玻璃体视网膜手术 Proliferative diabetic retinopathy Ranibizumab Intravitreal injection Vitreoretinalsurgery
  • 相关文献

参考文献12

  • 1Moss SE,Klein R, Klein BE. The 14-year incidence of visual loss in diabetic population[J]. Ophthalmology,1998,105(6):998 -1003.
  • 2Oyakawa RT, Scbachat AP, Michels RG, et al. Complications of vitreous surgery for diabetic retinopathy I Intraoperative compli- cations[J]. Ophthalmology, 1983,90(5) :517-521.
  • 3Ribeiro JA,Messias A,de Almeida FP,et al.The effect of intra- vitreal ranibizumab on intraoperative bleeding during pars pla- na vitrectomy for diabetic traction retinal detachment[J].Br J Ophthalmol,2011,95 (9) : 1337-1339.
  • 4中华医学会眼科学分会眼底病学组.糖尿病视网膜病变分期标准[J].眼底病,1985,1(1):42.
  • 5刘鹤南,朱颖,陈晓隆,陆岩.肾素-血管紧张素系统阻滞剂预防早产儿视网膜病变研究[J].中华眼底病杂志,2010,26(3):291-293. 被引量:10
  • 6Modarres M, Nazari H, Falavarjeni KG, et al.Intravitreal iniec- tion of bevacizumab before vitreetomy for proliferative diabetic retinopathy[J].Eur J Ophthalmol, 2009,19(5) : 848-852.
  • 7Ishikawa K,Honda S,Tsukahara Y,et al.Preferable use of intra- vitreal bevacizumab as a pretreatment of vitmetomy for_severe proliferative diabetic retinopathy[J].Eye,2009,23(1):108-111.
  • 8Di Lauro R1,De Ruggiero P,di Lauro R,et al.Intravitreal beva- cizumab for surgical treatment of severe proliferative diabetic retinopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2010, 248 (6) :785-791.
  • 9Chen El,Park CH. Use of intravitreal bevacizumab as a preop- erative adjunct for tractional retinal detachment repair in se- vere proliferative diabetic retinopathy [J]. Retina, 2006, 26 (6) : 699-700.
  • 10Ahmadieh H1,Shoeibi N,Entezari M,et al. Intravitreal bevaci- zumab for prevention of early postvitrectomy hemorrhage in dia- betic patients: a randomized clinical trial [J]. Ophthalmology, 2009,116(10) 1943-1948.

二级参考文献50

  • 1Heckmann M.Pathogenesis of retinopathy of prematurity.Ophthalmologe,2008,105:1101-1107.
  • 2Downie LE.Pianta MJ,Vingrys AJ,et al.AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxygen-induced retinopathy.Glia,2008,56:1076-1090.
  • 3Suzuki Y,Ruiz-Ortega M,Lorenzo O,et al.Inflammation and angiotensin Ⅱ.Int J Biochem Cell Biol.2003,35:881-900.
  • 4Singh VP,Le B,Khode R,et al.Intracellular angiotensin Ⅱ production in diabetic rats is correlated with cardiomyocyte apoptosis,oxidative stress,and cardiac fibrosis.Diabetes,2008,57:3297-3306.
  • 5Unger T.The role of the renin-angiotensin system in the development of cardiovascular disease.Am J Cardiol,2002,89:3-9.
  • 6Xu J,Carretero OA,Lin CX,et al.Role of cardiac overexpression of ANG Ⅱ in the regulation of cardiac function and remodeling postmyocardial infarction.Am J Physiol Heart Circ Physiol,2007,293:1900-1907.
  • 7Herr D,Rodewald M,Fraser HM,et al.Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative breast cancer.Gynecol Oncol,2008,109:418-425.
  • 8Sarlos S,Rizkalla B.Moravski CJ,et al.Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor,VEGF,and angiopoietin.Am J Pathol,2003,163:879-887.
  • 9Sarlos S,Wilkinson-Berka JL.The renin-angiotensin system and the developing retinal vasculature.Invest Ophthalmol Vis Sci,2005,46:1069-1077.
  • 10Wagner J,Jan Danser AH,Derkx FH,et al.Demonstration of renin mRNA,angiotensinogen mRNA,and angiotensin converting enzyme mRNA expression in the human eye:evidence for an intraocular renin-angiotensin system.Br J Ophthalmol,1996,80:159-163.

共引文献9

同被引文献65

引证文献10

二级引证文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部